Table 3.

Analysis of Overall Survival Defined From the Date of Diagnosis of Metastatic Disease

KRAS Statusa	No. of Patients	Median OS (95% CI), mo	3-Year Survival Estimate (95% CI)	5-Year Survival Estimate (95% CI)	Pb
Synchronous group
WT	39	36.3 (21.8–58.3)	0.51 (0.33–0.66)	0.28 (0.12–0.46)	.55
Mutant	25	40.3 (27.3–51.0)	0.59 (0.36–0.77)	0.16 (0.03–0.38)
Metachronous group
WT	31	33.2 (28.3–49.4)	0.43 (0.24–0.62)	0.27 (0.11–0.47)	.33
Mutant	15	53.0 (26.7 to NA)	0.53 (0.23–0.76)	0.27 (0.02–0.65)
Combined groupc
WT	70	34.3 (28.3–49.4)	0.50 (0.37–0.62)	0.28 (0.16–0.41)	.91
Mutant	40	40.3 (27.9–51.1)	0.53 (0.35–0.69)	0.17 (0.04–0.39)
Total
WT and mutant	110	35.2 (30.5–49.4)	0.50 (0.39–0.60)	0.25 (0.15–0.37)

Abbreviations: CI, confidence interval; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; NA, not applicable; OS, overall survival; WT, wild type.

^aPatients in the synchronous group had metastatic disease at the time of diagnosis; patients in the metachronous group developed metastases after their initial diagnosis of localized disease.

^bP values for OS were calculated with the log-rank test.

^cThe synchronous and metachronous groups combined.